Exelixis (EXEL) : 4 brokerage houses believe that Exelixis (EXEL) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Exelixis (EXEL). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.4.
Exelixis (EXEL) : The highest short term price target forecast on Exelixis (EXEL) is $12 and the lowest target price is $8. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $10.67 with a standard deviation of $2.31.
Also, In a research note released to the investors, Stifel Nicolaus maintains its rating on Exelixis (NASDAQ:EXEL).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Stifel Nicolaus raises the new price target from $10 per share to $12 per share. The rating by the firm was issued on August 4, 2016.
Exelixis (NASDAQ:EXEL): After opening at $12.93, the stock dipped to an intraday low of $12.93 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $13.49 and the buying power remained strong till the end. The stock closed at $13.34 for the day, a gain of 2.54% for the day session. The total traded volume was 5,685,969. The stocks close on the previous trading day was $13.01.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).